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Background and aims: Besides the promise of great benefits of nanotechnology, concerns exist on 
adverse health consequences. As complexity and uncertainty are large, evidence-based policy will be 
elusive, and models of risk governance are needed. 
Methods: A critical assessment was conducted of key evidence on possible health implications of 
nanomaterials, with a view to identify options for risk governance and policy formulation. 
Results: Current evidence is far from being conclusive. A cautionary approach in policy may be 
appropriate for several reasons: (i) humans have limited evolutionary experience of nanomaterials- a 
possible reason for the diminishing ability of cells to interact with particles at nanoscale level; (ii) 
nanoparticles can enter the body relatively easily, especially through inhalation and gastro-intestinal 
assimilation, and are very mobile once inside the body; (iii) several chemical-physical mechanisms 
resulting in cell damage have been reported; (iv) effects are often dependent on particle size, with a 
tendency to become more active as the particle size decreases; (v) population exposure to nanomaterials 
is not well known, but may be or become high, for example through cosmetics, food additives, or from 
airborne nanoparticles; (vi) potential adverse effects include a broad spectrum of adverse effects, 
specific and a-specific.  
Conclusions: Assessing the risks of nanotechnology is challenging. One must take into account the 
unique complexities of the interaction with the human body. Innovative models and frameworks for risk 
assessment and risk governance are being developed and applied in order to inform policy. 
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